SKI-606 (Bosutinib)

DRUG4 trials

Sponsors

Pfizer, Wyeth is now a wholly owned subsidiary of Pfizer

Conditions

Breast NeoplasmsChronic Myelogenous LeukemiaHealthyNeoplasm Metastasis

Phase 1

Study Comparing Two Different Tablet Formulations Of Bosutinib

CompletedNCT00934674

Wyeth is now a wholly owned subsidiary of PfizerHealthy

Start: 2009-07-31End: 2009-08-31Target: 30Updated: 2009-09-02

Study Comparing Two Different Tablet Formulations Of Bosutinib Under Fed Conditions

CompletedNCT01080365

Wyeth is now a wholly owned subsidiary of PfizerHealthy

Start: 2010-02-28End: 2010-03-31Updated: 2010-09-06

Phase 2

Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer

CompletedNCT00319254

PfizerBreast Neoplasms, Neoplasm Metastasis

Start: 2006-05-31End: 2009-02-28Updated: 2013-01-31

Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias

CompletedNCT00811070

PfizerChronic Myelogenous Leukemia

Start: 2007-12-31End: 2015-06-30Updated: 2016-06-28

Related Papers

PB1966: THE EFFECT OF BODY MASS INDEX ON THE SAFETY OF BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A POST HOC POOLED DATA ANALYSIS

HemaSphere2023-08-01

Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis.

2022-03-026 citations

Induced pluripotent stem cell–based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients

BMJ Open2019-12-0146 citations

Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.

2017-04-136 citations